

Horizons Psychedelic Stock Index ETF (PSYK:NEO)

Summary of Investment Portfolio *As at March 31*, 2022

			% of ETF's
Asset Mix	Net Asset Value		Net Asset Value
Canadian Equities	\$	13,119,552	49.26%
Global Equities		8,506,478	31.94%
U.S. Equities		4,876,807	18.31%
Cash and Cash Equivalents		150,114	0.56%
Other Assets less Liabilities		(19,112)	-0.07%
	\$	26,633,839	100.00%

		% of ETF's
Sector Mix	Net Asset Value	Net Asset Value
Health Care	\$ 26,174,107	98.27%
Financials	305,460	1.15%
Consumer Staples	23,270	0.09%
Cash and Cash Equivalents	150,114	0.56%
Other Assets less Liabilities	(19,112)	-0.07%
	\$ 26,633,839	100.00%



Horizons Psychedelic Stock Index ETF (PSYK:NEO)

Summary of Investment Portfolio (continued)

As at March 31, 2022

	% of ETF's
Top Holdings	Net Asset Value
GH Research PLC	11.73%
Mind Medicine (MindMed) Inc.	10.64%
Compass Pathways PLC	10.32%
atai Life Sciences NV	9.89%
Cybin Inc.	9.41%
Numinus Wellness Inc.	9.32%
Seelos Therapeutics Inc.	7.61%
Field Trip Health Ltd.	7.07%
AbbVie Inc.	5.19%
Johnson & Johnson	5.07%
Revive Therapeutics Ltd.	4.46%
Mindset Pharma Inc.	3.97%
Greenbrook TMS Inc.	1.75%
Red Light Holland Corp.	1.15%
Optimi Health Corp.	0.59%
Cash and Cash Equivalents	0.56%
Mydecine Innovations Group Inc.	0.45%
Enveric Biosciences Inc.	0.44%
PharmaTher Holdings Ltd.	0.21%
HAVN Life Sciences Inc.	0.15%
Psyched Wellness Ltd.	0.09%

The summary of investment portfolio may change due to the ongoing portfolio transactions of the ETF. The ETF's most recent financial statements are available at no cost by calling toll free 1-866-641-5739, or (416) 933-5745, by writing to us at Horizons ETFs Management (Canada) Inc., 55 University Avenue, Suite 800, Toronto, Ontario, M5J 2H7, by visiting our website at www.horizonsetfs.com or through SEDAR at www.sedar.com.